NASDAQ:FTSV Forty Seven (FTSV) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free FTSV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$95.51▼$95.5150-Day Range$95.51▼$95.5152-Week Range$5.53▼$95.51VolumeN/AAverage Volume1.61 million shsMarket Capitalization$4.60 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Forty Seven alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Forty Seven Stock (NASDAQ:FTSV)Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide FTSV Stock News HeadlinesApril 9, 2024 | msn.com49ers sign veteran tight endMarch 28, 2024 | msn.comParent Of FTX Victim Who Lost $130K Recommends Six-Year Sentence For Sam Bankman-Fried, Countering DOJ's 40-50 YearsApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.November 16, 2023 | morningstar.comFormula Systems (1985) Ltd ADR FORTYOctober 27, 2023 | nypost.comSix young men found dead, one injured in search for seven abducted Mexican teenagersOctober 10, 2023 | bizjournals.com$18M upgrade makes historic downtown Milwaukee high-rise a modern data centerSeptember 11, 2023 | msn.comTampa radio station 101.5 has changed from Top 40 to R&B formatAugust 18, 2023 | msn.comJRA Chair: Seven businesses coming to Farish StreetApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.June 11, 2023 | dailymail.co.ukWeek one: seven-day detoxApril 18, 2023 | dailymail.co.ukI'm a fitness coach. These are the seven exercises that are a complete waste of your timeMarch 22, 2023 | thetimes.co.ukForty racists beat me with sticks in the name of a conspiracy theoryJanuary 2, 2023 | finance.yahoo.comForty-Five Percent of Public Schools Operating Without a Full Teaching Staff in October, New NCES Data ShowOctober 1, 2022 | bizjournals.comMeet our Forty Under 40 winnersJune 18, 2022 | news.yahoo.comSouth wins 51st Ken Lantzy Finest 40 All-Star Classic in shootoutMay 27, 2022 | investing.comFTSV_old Historical DataSee More Headlines Receive FTSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FTSV CUSIPN/A CIKN/A Webwww.fortyseveninc.com Phone650-352-4150FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.38% Return on Assets-44.35% Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81 Sales & Book Value Annual Sales$15.68 million Price / Sales293.33 Cash FlowN/A Price / Cash FlowN/A Book Value$7.52 per share Price / Book12.70Miscellaneous Outstanding Shares48,156,000Free FloatN/AMarket Cap$4.60 billion OptionableNot Optionable Beta0.40 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Mark A. McCamish (Age 66)Pres, CEO & Director Dr. Craig S. Gibbs (Age 56)Chief Bus. Officer Dr. Chris H. Takimoto M.D. (Age 60)Ph.D., Chief Medical Officer Mr. Mark ChaoFounder & VP of Clinical Devel.Mr. Jens-Peter VolkmerFounder and VP of Research & Early Devel.Key CompetitorsBridgeBio PharmaNASDAQ:BBIOOrganon & Co.NYSE:OGNMadrigal PharmaceuticalsNASDAQ:MDGLNuvalentNASDAQ:NUVLAlpine Immune SciencesNASDAQ:ALPNView All Competitors FTSV Stock Analysis - Frequently Asked Questions How were Forty Seven's earnings last quarter? Forty Seven Inc (NASDAQ:FTSV) issued its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.38). The company earned $15.68 million during the quarter, compared to analyst estimates of $15.80 million. What other stocks do shareholders of Forty Seven own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer (ET), TG Therapeutics (TGTX), Gilead Sciences (gild), Unisys (UIS), Inovio Pharmaceuticals (INO), GlycoMimetics (GLYC), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD) and Sarepta Therapeutics (SRPT). When did Forty Seven IPO? Forty Seven (FTSV) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers. This page (NASDAQ:FTSV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forty Seven Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
